279 results
8-K
EX-99.1
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
(Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Received "no action indicated" (NAI) status for Baltimore Bayview Manufacturing Facility
8-K
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
of the U.S. Department of Health and Human Services (“HHS”), (“Modification 11”) which would reduce the minimum purchase dose quantity from 9.0 million
8-K
EX-10.1
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
activities against the United States, the Department of Health and Human Services (DHHS) and the Assistant Secretary for Preparedness and Response
8-K
EX-99.1
affri2ycxsznwt7l
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
8-K
EX-10.1
ltc5zdpx7vdq 64r
21 Feb 24
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
7:25am
8-K
6e03y2awv7n38h4ln5
11 Jan 24
Other Events
7:41am
8-K
EX-99.1
0extzsvzrznzljft
11 Jan 24
Other Events
7:41am
8-K
b6p sxv02uhy3omdfhsn
28 Nov 23
Other Events
7:15am
8-K
EX-99.1
txngi85j tu90
28 Nov 23
Other Events
7:15am
8-K
EX-99.1
9pq9xdok0utrg
31 Jul 23
Other Events
4:26pm
8-K
EX-99.1
mkq7auw
21 Jul 23
Regulation FD Disclosure
8:25am
8-K
EX-99.1
qfvnzuw sumc
30 May 23
Entry into a Material Definitive Agreement
7:32am
8-K
m0c7o9l1
30 May 23
Entry into a Material Definitive Agreement
7:32am
8-K
EX-10.1
7v3p 9x03pyh8yjmaj
17 May 23
Emergent’s Statement Regarding its Amended Credit Agreement
9:32pm